Associate Professor Eiji Oki
Faculty of Medical Sciences
A research group led by Dr. Takayuki Yoshino, Deputy Director, and Dr. Yoshiaki Nakamura, Chief of the International Research Promotion Office at National Cancer Center Hospital East of the National Cancer Center, along with Associate Professor Eiji Oki from Kyushu University, investigated the relationship between liquid biopsy results and cancer recurrence risk and survival time for 2,240 patients with colorectal cancer participating in the CIRCULATE-Japan GALAXY trial.
The results showed that patients with detectable circulating tumor DNA (ctDNA) in post-operative blood tests had a higher risk of cancer recurrence and shorter survival time compared to those without detectable ctDNA. Furthermore, it was revealed that even among patients with detectable ctDNA, those who received post-operative adjuvant chemotherapy and subsequently cleared ctDNA had a lower risk of recurrence.
These research findings scientifically demonstrate that examining ctDNA can predict the risk of colorectal cancer recurrence and survival time, aiding in treatment decision-making. This research was published in Nature Medicine on September 16, 2024, at 10:00 a.m. (London time).
Research-related inquiries
Eiji Oki, Associate Professor
Faculty of Medical Sciences
Contact information can also be found in the full release
